Medical Oncology

, 35:105 | Cite as

α-Viniferin activates autophagic apoptosis and cell death by reducing glucocorticoid receptor expression in castration-resistant prostate cancer cells

  • Kejun Cheng
  • Xi Liu
  • Lu Chen
  • Jian-Min Lv
  • Fa-Jun Qu
  • Xiu-Wu Pan
  • Lin Li
  • Xin-Gang Cui
  • Yi GaoEmail author
  • Dan-Feng Xu
Original Paper


Prostate cancer (PCa) is one of the most commonly diagnosed urological malignancies. However, there are limited therapies for PCa patients who develop biochemical recurrence after androgen deprivation therapy (ADT). In the present study, we investigated the therapeutic efficacy and mechanism of α-Viniferin (KCV), an oligostilbene of trimeric resveratrol, against human PCa cells and found that it markedly inhibited the proliferation of LNCaP, DU145, and PC-3 cancer cells in a time- and dose-dependent manner, and had a strong cytotoxicity in non-androgen-dependent PCa cells. In addition, KCV inhibited AR downstream expression in LNCaP cells, and inhibited activation of GR signaling pathway in DU145 and PC-3. Further investigation indicated that KCV could induce cancer cell apoptosis through AMPK-mediated activation of autophagy, and inhibited GR expression in castration-resistant prostate cancer(CRPC). These findings suggest that KCV may prove to be a novel and effective therapeutic agent for the treatment of CRPC.


α-Viniferin Autophagy Prostate cancer Glucocorticoid receptor AMPK 



This work was supported by grants from the National Natural Science Foundation of China (No. 81572525; No. 81170637).

Compliance with ethical standards

Conflict of interest

There is no conflict of interest in this manuscript.


  1. 1.
    Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016; 71:618.CrossRefPubMedGoogle Scholar
  2. 2.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol Off. 2008;26:1148.CrossRefGoogle Scholar
  3. 3.
    Szekeres T, Fritzer-Szekeres M, Saiko P, et al. Resveratrol and resveratrol analogues—structure—activity relationship. Pharm Res-Dordr. 2010;27:1042–8.CrossRefGoogle Scholar
  4. 4.
    Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009;486:95–102.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sebastiano C, Giuseppe S, Vincenzo F, et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev. 2012. CrossRefGoogle Scholar
  6. 6.
    Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008 29: 2001–10.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ferruelo A, Romero I, Cabrera PM, et al. Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas Urol Esp. 2014;38:397–404.CrossRefPubMedGoogle Scholar
  8. 8.
    Xie N, Cheng H, Lin D, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2015;136:E27–38.CrossRefGoogle Scholar
  9. 9.
    Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309–22.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Høyer-Hansen M, Jäättelä M. AMP-activated protein kinase: a universal regulator of autophagy?. Autophagy. 2007; 3:381–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol Off. 2011;29:3651–8.CrossRefGoogle Scholar
  12. 12.
    Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24:251–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138:245–56.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wright AP, Zilliacus J, Mcewan IJ, et al. Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol. 1993;47:11.CrossRefPubMedGoogle Scholar
  15. 15.
    Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013;73:1570–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lee MH, Kundu JK, Keum YS, et al. Resveratrol inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol Ther (Seoul). 2014; 22:426–30.Google Scholar
  18. 18.
    Mitani T, Harada N, Tanimori S, et al. Resveratrol inhibits hypoxia-inducible factor-1 alpha-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. J Nutr Sci Vitaminol (Tokyo). 2014; 60:276–82.CrossRefGoogle Scholar
  19. 19.
    Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 2015;33:1–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Ratman D, Mylka V, Bougarne N, et al. Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα. Nucleic Acids Res. 2016;44:10539–53.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vergis R, Corbishley CM, Norman AR, et al., Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008; 9:342–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Ryter SW, Mizumura K, Choi AMK. The impact of autophagy on cell death modalities. Int J Cell Biol. 2014;2014:502676.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jing K, Lim K. Why is autophagy important in human diseases? Exp Mol Med. 2012;44:69–72.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gump JM, Thorburn A. Autophagy and apoptosis—what’s the connection? Trends Cell Biol. 2011; 21:387–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013;2013:102735.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 1900; 3:542–5.CrossRefGoogle Scholar
  27. 27.
    Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol. 2008;445:77–88.CrossRefPubMedGoogle Scholar
  28. 28.
    Yamaguchi M, Noda NN, Yamamoto H, et al. Structural insights into Atg10-mediated formation of the autophagy-essential Atg12-Atg5 conjugate. Structure. 2012;20:1244–54.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Chemical Biology Center, Lishui Institute of Agricultural SciencesLishuiChina
  2. 2.Department of UrologyRuijin Hospital, Shanghai Jiaotong University School of MedicineShanghaiChina
  3. 3.Department of UrologyThird Affiliated Hospital, Second Military Medical UniversityShanghaiChina

Personalised recommendations